BioSpace News Archive

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced two-year follow up results from four Duchenne muscular dystrophy (DMD) clinical trial participants who received SRP-9001 (AAVrh74.MHCK7.micro-dystrophin).

Castellum, Inc. (OTC: ONOV) announces that it has signed an LOI to acquire a U.S. based government contracting company (the “Company”).

Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) released positive Phase 1b trial data (clinicaltrials.gov NCT03542838) of resiniferatoxin (RTX) with completed Day 84 effectiveness data (end-point analysis) for all patients and completed six-month follow-ups in all doses for all patients enrolled, with no negative safety signal as of September 2020.

Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will present on its lead vaccine candidates, NVX-CoV2373, NanoFlu™ and ResVax™, the Company’s COVID-19, influenza and respiratory syncytial virus (RSV) vaccines.

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its third quarter 2020 results on Thursday, October 29, 2020 at 12 p.m. London time (8 a.m. Eastern Daylight Time).

Certilytics, Inc. has been named a finalist for a Cloudera Data Impact Award, a recognition of Certilytics’ industry-leading technology ecosystem that processes massive healthcare data sets to produce sophisticated predictive intelligence for health plans, PBMs, government entities, and provider health systems.

A landmark study published in the American Association of Cancer Research’s (AACR) prestigious journal ‘Cancer Prevention Research’ has shown that it is possible to identify healthy individuals with higher risk of cancer based on a simple blood draw.

From the Science of Beer to learning about the benefits of GMOs; Saskatchewan is celebrating science with exciting online events and activities that showcase the province’s bioscience sector.

Sapreme announced positive preclinical data on its proprietary endosomal escape platform in two presentations at the 16th Annual Meeting of the Oligonucleotide Therapeutics Society, held virtually from September 27th to 30th, 2020.

According to the report, the global homeopathic product market was valued at US$ 5.6 Bn in 2018 and is projected to expand at a CAGR of ~14% from 2019 to 2027.